# A Study to Evaluate the Pharmacokinetics of HSK21542 in Subjects With Renal Impairment

> **NCT05947097** · PHASE1 · UNKNOWN · sponsor: **Haisco Pharmaceutical Group Co., Ltd.** · enrollment: 32 (estimated)

## Conditions studied

- Renal Impairment

## Interventions

- **DRUG:** HSK21542 Injection

## Key facts

- **NCT ID:** NCT05947097
- **Lead sponsor:** Haisco Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-04-24
- **Primary completion:** 2023-07-30
- **Final completion:** 2023-12-30
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2023-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05947097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05947097, "A Study to Evaluate the Pharmacokinetics of HSK21542 in Subjects With Renal Impairment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05947097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*